Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Samtani MN, Raghavan N, Shi Y, Novak G, Farnum M, Lobanov V, Schultz T, Yang E, DiBernardo A, Narayan VA; Alzheimer's Disease Neuroimaging Initiative.

Br J Clin Pharmacol. 2013 Jan;75(1):146-61. doi: 10.1111/j.1365-2125.2012.04308.x.

2.

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.

3.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

4.

An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.

Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, Dibernardo A, Narayan V; Alzheimer’s Disease Neuroimaging Initiative.

J Clin Pharmacol. 2012 May;52(5):629-44. doi: 10.1177/0091270011405497. Epub 2011 Jun 9.

PMID:
21659625
5.

Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.

Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.

J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.

PMID:
25322924
6.

Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.

Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(3):729-40. doi: 10.3233/JAD-150066.

PMID:
26401707
7.

Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?

Ye BS, Lee WW, Ham JH, Lee JJ, Lee PH, Sohn YH; Alzheimer's Disease Neuroimaging Initiative.

Eur J Neurol. 2016 May;23(5):948-57. doi: 10.1111/ene.12969. Epub 2016 Feb 24.

PMID:
26917248
8.

Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.

Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Arch Gen Psychiatry. 2011 Sep;68(9):961-9. doi: 10.1001/archgenpsychiatry.2011.96.

PMID:
21893661
9.

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.

Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, Lamontagne J, Chelsky D, Hoffmann S, Potter WZ; Alzheimer's Disease Neuroimaging Initiative; Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team.

Proteomics Clin Appl. 2015 Aug;9(7-8):715-31. doi: 10.1002/prca.201400178. Epub 2015 Apr 24.

10.

Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.

Llano DA, Laforet G, Devanarayan V; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):73-84. doi: 10.1097/WAD.0b013e3181f5b8d8.

PMID:
20847637
11.

Injury markers predict time to dementia in subjects with MCI and amyloid pathology.

van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ.

Neurology. 2012 Oct 23;79(17):1809-16. doi: 10.1212/WNL.0b013e3182704056. Epub 2012 Sep 26.

12.

Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.

Samtani MN, Raghavan N, Novak G, Nandy P, Narayan VA.

Neuropsychiatr Dis Treat. 2014 May 24;10:929-52. doi: 10.2147/NDT.S62323. eCollection 2014.

13.

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ.

Neurobiol Aging. 2012 Oct;33(10):2272-81. doi: 10.1016/j.neurobiolaging.2011.12.017. Epub 2012 Jan 20.

PMID:
22264648
14.

Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.

Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, Siemers ER, Martenyi F, Tauscher JT, Schwarz AJ.

J Alzheimers Dis. 2012;32(2):373-85. doi: 10.3233/JAD-2012-120832.

PMID:
22796873
15.

Longitudinal changes of CSF biomarkers in Alzheimer's disease.

Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.

J Alzheimers Dis. 2011;25(4):583-94. doi: 10.3233/JAD-2011-101911.

PMID:
21460434
16.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

17.

Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.

Marshall GA, Lorius N, Locascio JJ, Hyman BT, Rentz DM, Johnson KA, Sperling RA.

J Alzheimers Dis. 2014;41(3):719-28. doi: 10.3233/JAD-132768.

18.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
19.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

20.

Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data.

Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Nov;10(6):704-12. doi: 10.1016/j.jalz.2013.11.009. Epub 2014 Mar 6.

Supplemental Content

Support Center